NeOnc CEO buys ~$300k NTHI stock; FY2025 net loss $62M, mostly non-cash; clinical catalysts ahead

NEONC TECHNOLOGIES HOLDINGS, INC.

CEO Amir Heshmatpour purchased ~$300k of NTHI common stock in the past week, signaling confidence.
FY2025 net loss ~$62M; ~$45.2M was non-cash stock comp ($35.6M) and one-time listing fees ($9.6M); normalized cash op ex ~$10.1M.
NEO100 Phase 2a interim data readout expected ~August 2026 (within ~4 months).
NEO212 Type B End-of-Phase FDA meeting within ~4 weeks to align on potential registrational Phase 2 study.
Q1 2026 private placement raised ~$13M gross; proceeds used to repay convertible debt and obligations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.